Assay for Sars Coronavirus by Amplification and Detection of the Replicase Sequence

ABSTRACT

Primers and probes derived from SARS-CoV nucleic acid that facilitate detection and/or quantification of the replicase gene are disclosed. The disclosed sequences may be used in a variety of amplification and non-amplification formats for detection of SARS-CoV infection.

The present application claims priority to U.S. Provisional ApplicationSer. No. 60/502,279, filed Sep. 12, 2003, which is herein incorporatedby reference in its entirety.

TECHNICAL FIELD

The present invention relates to methods to assay for the presence ofSevere Acute Respiratory Syndrome coronavirus by amplification anddetection of the replicase RNA sequence.

BACKGROUND ART

Severe acute respiratory syndrome (SARS) is a recently emerging diseaseassociated with atypical pneumonia in infected patients. The disease isunusually severe, and there is no known treatment. The incubation periodfor SARS is typically between 2 and 10 days. Sympathkumar et al., MayoClin. Proc. 78: 882-890 (2003). Physical manifestations of SARS includefever, followed by a dry, nonproductive cough and shortness of breath.Death from respiratory failure occurs in about 3% to 10% of SARS cases.Centers for Disease Control and Prevention (CDC). Morb. Mortal. Wkly.Report. 52: 357 (2003).

Clinical diagnosis of SARS is often a slow process because initialdiagnostic testing of suspected SARS patients includes a chestradiograph, pulse oximetry, blood culture, sputum Gram's stain andculture, and testing for other viral respiratory infections. CDC,Guidelines and Recommendations: Interim Guidelines for LaboratoryDiagnosis of SARS-CoV Infection, Jul. (2003). This difficulty is alsoreflected by the fact that two of the most common diagnosticprocedures-detection of serum antibodies to the SARS virus and isolationin cell culture of the virus from a clinical specimen-often take days oreven weeks to complete. CDC, Guidelines and Recommendations: InterimGuidelines for Laboratory Diagnosis of SARS-CoV Infection, Jul. (2003).Thus, the need for the establishment of a rapid and noninvasive test forSARS is essential for monitoring and control of the disease.

Early in 2003, a novel coronavirus was identified as the causative agentof SARS. Drosten et al., N. Engl. J. Med 348: 1967-76 (2003). Thecoronaviruses are a diverse group of RNA viruses that cause respiratoryand enteric diseases in humans and other animals. They are the largestof the RNA viruses, with a genome of approximately 30,000 nucleotides.Rota et al., Science 300:1394-1399 (2003). The SARS-Coronavirus(SARS-CoV) is an enveloped, positive-stranded RNA virus. Based onsequence analysis, SARS-CoV is a member of a new group of coronavirus(order Nidovirales, Family Coronaviridae, genus Coronavirus). Rota etal., supra.

The replicase (rep) gene, is located towards the 5′ end of the genomicRNA and comprises approximately 70% of the whole genome. In contrastwith other viral proteins, the rep gene products are translated from thegenomic RNA. The replicase polyprotein undergo autocatalytic cleavage toyield functional viral proteases, RNA polymerase and RNA-dependenthelicase. Detection of the rep gene may be used as an indicator of thepresence of genomic SARS-CoV RNA. Rota et al., supra. An assay thattests for the presence of the viral nucleic acid would therefore allowfor the rapid and sensitive detection of SARS-CoV. Such an assay wouldprovide a more sensitive alternative to serological testing, directfluorescent antibody staining or urinary antigen testing.

DISCLOSURE OF INVENTION

According to one aspect, the present invention provides anoligonucleotide set comprising a first amplification primer and a secondamplification primer, the first amplification primer selected from thegroup consisting of SEQ ID NOs.: 2 and 14 and the second amplificationprimer selected from the group consisting of SEQ ID NOs.: 3 and 15. Inanother aspect, the first amplification primer consists essentially ofSEQ ID NO.: 2 and the second amplification primer consists essentiallyof SEQ ID NO.: 3. In yet another aspect of the present invention, thefirst amplification primer consists essentially of SEQ ID NO.: 14 andthe second amplification primer consists essentially of SEQ ID NO.: 15.

According to an additional aspect, the present invention provides anoligonucleotide set comprising a first amplification primer and a secondamplification primer, the first amplification primer selected from thegroup consisting of the target binding sequences of SEQ ID NOs.: 2 and14 and the second amplification primer selected from the groupconsisting of the target binding sequences SEQ ID NOs.: 3 and 15. Inanother aspect, the first amplification primer consists essentially ofthe target binding sequence of SEQ ID NO.: 2 and the secondamplification primer consists essentially of the target binding sequenceof SEQ ID NO.: 3. In yet another aspect of the present invention, thefirst amplification primer consists essentially of the target bindingsequence of SEQ ID NO.: 14 and the second amplification primer consistsessentially of the target binding sequence of SEQ ID NO.: 15.

According to a further aspect, the oligonucleotide set further comprisesa signal primer and a reporter probe, the signal primer selected fromthe group consisting of the target binding sequences of SEQ ID NOs.: 4,5, 16 and 17 and the reporter probe selected from the group consistingof SEQ ID NOs.: 8 and 10. In one aspect, the signal primer consistsessentially of the target binding sequence of SEQ ID NO.: 4 and thereporter probe consists essentially of SEQ ID NO.: 8. In yet anotheraspect, the signal primer consists essentially of the target bindingsequence of SEQ ID NO.: 5 and the reporter probe consists essentially ofSEQ ID NO.: 10 According to a further aspect, the oligonucleotide setfurther comprises a second reporter probe consisting essentially of SEQID NO.: 11. In a further embodiment, the oligonucleotide set with asecond reporter probe further comprises one or more bumper primersselected from the group consisting of SEQ ID NOs.: 1, 12 and 13.

In an additional embodiment, the signal primer consists essentially ofthe target binding sequence of SEQ ID NO.: 16 and the reporter probeconsists essentially of SEQ ID NO.: 8. In yet another embodiment of thepresent invention, the signal primer consists essentially of the targetbinding sequence of SEQ ID NO.: 17 and the reporter probe consistsessentially of SEQ ID NO.: 10. In a further aspect, the oligonucleotideset further comprises a second signal primer and a second reporterprobe, the second signal primer consisting essentially of SEQ ID NO.: 17and the second reporter probe consisting essentially of thehybridization sequence of SEQ ID NO.: 10. In still another aspect, theoligonucleotide set comprising a second signal primer and a secondreporter probe further comprises one or more bumper primers selectedfrom the group consisting of SEQ ID NOs.: 1, 12 and 13.

According to a further aspect, the target binding sequences of SEQ IDNOs.: 2, 3, 14 and 15 comprise a sequence required for an amplificationreaction. In another embodiment of the present invention, the sequencerequired for the amplification reaction comprises a restrictionendonuclease recognition site that is nickable by a restrictionendonuclease. In yet another embodiment, the sequence required for theamplification reaction comprises a promoter recognized by an RNApolymerase. In still another embodiment, the hybridization sequences ofSEQ ID NOs.: 4, 5, 8, 9, 10, 11, 16 and 17 further comprise anindirectly detectable marker. In another aspect, the indirectlydetectable marker comprises an adapter sequence.

In a further embodiment, the present invention provides anoligonucleotide comprising a SARS-CoV target sequence selected from thegroup consisting of SEQ ID NOs.: 6, 7, 18 and 19.

In another embodiment, the present invention provides a method fordetecting the presence or absence SARS-CoV in a sample, the methodcomprising: (a) treating the sample with a plurality of nucleic acidprimers in a nucleic acid amplification reaction wherein a first primeris selected from the group consisting of the target binding sequences ofSEQ ID NO.: 2 and SEQ ID NO.: 14 and a second primer is selected fromthe group consisting of the target binding sequences of SEQ ID NO.: 3and SEQ ID NO.: 15; and (b) detecting any amplified nucleic acidproduct, wherein detection of the amplified product indicates presenceof SARS CoV. In a further embodiment, the first primer consistsessentially of SEQ ID NO.: 2 and the second primer consists essentiallyof SEQ ID NO.: 3. In yet another embodiment, the first primer consistsessentially of SEQ ID NO.: 14 and the second primer consists essentiallyof SEQ ID NO.: 15. In still another embodiment, step (a) comprises aStrand Displacement Amplification (SDA) reaction. In a furtherembodiment, the SDA reaction utilizes one or more bumper primersselected from the group consisting of SEQ ID NOs.: 1, 12 and 13. In yetanother embodiment, the SDA reaction comprises a thermophilic StrandDisplacement Amplification (tSDA) reaction. In an additional embodiment,the tSDA reaction is a homogeneous fluorescent real time tSDA reaction.In a further embodiment, step (b) includes the step of hybridizing saidamplified nucleic acid product with a signal primer selected from thegroup consisting of SEQ ID NOs.: 4, 5, 16 and 17.

According to a further aspect, the present invention provides a methodfor amplifying a target nucleic acid sequence of SARS-CoV comprising:(a) hybridizing to the nucleic acid (i) a first amplification primerselected from the group consisting of the target binding sequences ofSEQ ID NO.: 2 and 14; and (ii) a second amplification primer selectedfrom the group consisting of the target binding sequences of SEQ ID NO.:3 and 15; and (b) extending the hybridized first and secondamplification primers on the target nucleic acid sequence whereby thetarget nucleic acid sequence is amplified. According to a further aspectof the method, the first amplification primer consists essentially ofthe target binding sequence of SEQ ID NO.: 2 and the secondamplification primer consists essentially of the target binding sequenceof SEQ ID NO.: 3. According to a further aspect of the method, the firstamplification primer consists essentially of the target binding sequenceof SEQ ID NO.: 15 and the second amplification primer consistsessentially of the target binding sequence of SEQ ID NO.: 16.

In still another aspect of the method, the target binding sequences ofSEQ ID NO.: 2 and SEQ ID NO.: 3 comprise a sequence required for anamplification reaction. In another embodiment, the sequence required forthe amplification reaction comprises a restriction endonucleaserecognition site that is nickable by a restriction endonuclease. In yetanother embodiment, the sequence required for the amplification reactioncomprises a promoter recognized by an RNA polymerase.

In yet another aspect of the invention, the target binding sequences ofSEQ ID NO.: 15 and SEQ ID NO.: 16 comprise a sequence required for anamplification reaction. In a further aspect, the sequence required forthe amplification reaction comprises a restriction endonucleaserecognition site that is nickable by a restriction endonuclease. In afurther embodiment, the sequence required for the amplification reactioncomprises a promoter recognized by an RNA polymerase.

In a further aspect, the method either comprises indirectly detectingthe amplified target nucleic acid by hybridization to a signal primer.In yet another aspect, the signal primer is selected from the groupconsisting of SEQ ID NOs.: 4, 5, 16 and 17.

According to a further aspect, the target nucleic acid sequence isselected from the group consisting of SEQ ID NOs.: 6, 7, 18 and 19.

According to another aspect, the present invention provides a method ofquantifying the amount of SARS-CoV nucleic acid in a target samplecomprising the steps of: a) combining the target sample with a knownconcentration of SARS-CoV internal control nucleic acid; b) amplifyingthe target nucleic acid and internal control nucleic acid in anamplification reaction; c) detecting the amplified nucleic acid; and d)analyzing the relative amounts of amplified SARS-CoV target nucleic acidand internal control nucleic acid. In a further embodiment, step (b)comprises a strand displacement amplification reaction. In yet anotherembodiment of the method, the SDA reaction comprises a tsDA reaction.According to a further aspect, the amplification reaction utilizes oneor more signal primers selected from the group consisting of thehybridization sequences of SEQ ID NOs.: 4, 5, 16 and 17 and one or morereporter probes selected from the group consisting of the hybridizationsequences of SEQ ID NOs.: 8, 9, 10 and 11. According to yet anotheraspect, the hybridization sequences of SEQ ID NOs.: 4, 5, 8, 9, 10, 11,16 and 17 comprise an indirectly detectable marker. In a furtherembodiment, the indirectly detectable marker comprises an adaptersequence.

Modes for Carrying Out the Invention

The methods of the present invention are useful for assaying for thepresence of SARS-CoV by the amplification and detection of the SARS-CoVrep sequence. The primers and probes of the present invention are basedon portions of the SARS-CoV replicase gene. The present invention alsoprovides oligonucleotides that may be used in amplification, detectionand/or quantification of the rep gene. The oligonucleotides may be usedin all types of amplification reactions such as, for example, StrandDisplacement. Amplification (SDA), Polymerase Chain Reaction (PCR),Ligase Chain Reaction, Nucleic Acid Sequence Based Amplification(NASBA), Rolling Circle Amplification (RCA), Transcription MediatedAmplification (IMA) and QB Replicase-mediated amplification. The presentinvention further provides oligonucleotides that may be used inamplification, detection and/or quantification of the rep gene withsufficient specificity and sensitivity.

The methods of the present invention may be employed, for example, butnot by way of limitation, to test clinical specimens obtained fromsuspected SARS patients. The specimens, or test samples, may becollected from any source suspected of containing SARS nucleic acid. Foranimals, preferably, mammals, and more preferably, humans, the source ofthe test samples may include blood, bone marrow, lymph, hard tissues(e.g., liver, spleen, kidney, lung, ovary, etc.), sputum, feces, urine,upper and lower respiratory specimens and other clinical samples. Othersources may include veterinary and environmental samples, as well as invitro cultures. Those skilled in the art are capable of determiningappropriate clinical sources for use in diagnosis of SARS-CoV infection.

Definitions

The following definitions are provided for reason of clarity, and shouldnot be considered as limiting. Except where noted, the technical andscientific terms used herein are intended to have the same meaning ascommonly understood by one of ordinary skill in the art to which theinvention pertains.

An “amplification primer” is an oligonucleotide for amplification of atarget sequence by extension of the oligonucleotide after hybridizationto a target sequence or by ligation of multiple oligonucleotides thatare adjacent when hybridized to the target sequence. At least a portionof the amplification primer hybridizes to the target. This portion isreferred to as the target binding sequence and it determinestarget-specificity of the primer. In addition to the target bindingsequence, certain amplification methods require specialized non-targetbinding sequences in the amplification primer. These specializedsequences are necessary for the amplification reaction to proceed andtypically serve to append that specialized sequence to the target. Forexample, but not by of limitation, the amplification primers used in SDAinclude a restriction endonuclease recognition 5′ to the target bindingsequence, as disclosed in U.S. Pat. Nos. 5,455,166 and 5,270,184, eachof which is incorporated herein by reference. NASBA, Self-SustainingSequence Replication (3SR) and transcription-based amplification primersrequire an RNA polymerase promoter linked to the target binding sequenceof the primer. Linking such specialized sequences to a target bindingsequence for use in a selected amplification reaction is routine in theart. In contrast, amplification methods such as PCR, which do notrequire specialized sequences at the ends of the target, generallyemploy amplification primers consisting of only target binding sequence.

As used herein, the terms “primer” and “probe” refer to the function ofthe oligonucleotide. A primer is typically extended by polymerase orligation following hybridization to the target whereas a probe mayeither function by hybridization to the target or through hybridizationfollowed by polymerase-based extension. A hybridized oligonucleotide mayfunction as a probe if it is used to capture or detect a targetsequence, and the oligonucleotide may function as a primer when it isemployed as a target binding sequence in an amplification primer. Itwill therefore be appreciated that any of the target binding sequencesdisclosed herein for amplification, detection or quantification ofSARS-CoV may be used either as hybridization probes or as target bindingsequences in primers for detection or amplification, optionally linkedto a specialized sequence required by the selected amplificationreaction or to facilitate detection.

A “bumper” or “external primer” is a primer that anneals to a targetsequence upstream of (i.e., 5′ to) an amplification primer, such thatextension of the external primer displaces the downstream primer and itsextension product, i.e., a copy of the target sequence comprising theSDA restriction endonuclease recognition site is displaced. The bumperprimers, therefore, consist only of target binding sequences and aredesigned so that they anneal upstream of the amplification primers anddisplace them when extended. External primers are designated B₁ and B₂by Walker, et al., Nuc. Acids Res., 20:1692-1696 (1992). Extension ofexternal primers is one method for displacing the extension products ofamplification primers, but heating may also be suitable in certaincases.

A “reverse transcription primer” also consists only of target bindingsequences. It is hybridized at the 3′ end of an RNA target sequence toprime reverse transcription of the target. Extension of the reversetranscription primer produces a heteroduplex comprising the RNA targetand the cDNA copy of the RNA target produced by reverse transcription.The cDNA is separated from the RNA strand (e.g., by heating, RNase H, orstrand displacement) to make it single-stranded and available foramplification. Optionally, a second reverse transcription primer may behybridized at the 3′ end of the target sequence in the cDNA to primesecond strand synthesis prior to amplification. Optionally, a reversetranscription primer may also function as an amplification or bumperprimer.

The terms “target” and “target sequence” refer to nucleic acid sequences(DNA and/or RNA) to be amplified, replicated or detected. These includethe original nucleic acid sequence to be amplified and its complementarysecond strand, as well as either strand of a copy of the original targetsequence produced by amplification or replication of the targetsequence. “Amplification products,” “extension products” or “amplicons”are oligonucleotides or polynucleotides that comprise copies of thetarget sequence produced during amplification or replication of thetarget sequence.

The term “polymerase” refers to any of various enzymes, such as DNApolymerase, RNA polymerase, or reverse transcriptase that catalyze thesynthesis of nucleic acids on preexisting nucleic acid templates. A DNApolymerase assembles the DNA from deoxyribonucleotides, while RNApolymerase assembles the RNA from ribonucleotides.

Based on alignment of 25 SARS-CoV nucleotide sequences, two regions wereselected as target sequences for use in amplification of the replicaseregion, as shown in Tables 1 and 3.

In one embodiment of the present invention, Reverse Transcriptase-StrandDisplacement Amplification (RT-SDA) has been adapted for the detectionof SARS-CoV replicase RNA in both genomic and subgenomic RNA sequences.SDA is an isothermal (constant temperature) nucleic acid amplificationmethod. In SDA, displacement of single-stranded extension products,annealing of primers to the extension products (or the original targetsequence) and subsequent extension of the primers occur concurrently inthe reaction mix. Conventional SDA (performed at lower temperatures,usually about 35-45° C.) is described by G. Walker, et al., Proc. Natl.Acad. Sci. USA 89:393-396 (1992) and Walker, et al., Nuc. Acids Res.,supra. Detection of nucleic acids by SDA is described in detail in U.S.Pat. Nos. 5,455,166; 5,523,204; and 5,916,779, the entire teachings ofwhich are herein incorporated by reference. These patents providemethods for amplification of a target nucleic acid sequence (and itscomplementary strand) in a sample by endonuclease-mediated stranddisplacement. Additionally, U.S. Pat. No. 5,916,779 adapts SDA toreverse transcription amplification of RNA targets.

According to the present invention, the SARS-CoV target replicase RNA isextracted from a test sample. The SARS-CoV replicase RNA may be isolatedby any method known to those of skill in the art The replicase RNA isthen amplified in, for example, an RT-SDA process. The RT-SDA may beperformed as either a one-step process or a two-step process. Theone-step process concurrently generates and amplifies cDNA copies of theSARS-CoV target sequence.

In one embodiment, the one-step RT-SDA process utilizes firstamplification and bumper primers designed to allow for incorporation ofa restriction endonuclease site and for displacement of single strandedcDNA. The resulting cDNA is subsequently amplified by annealing ofsecond amplification and optionally one or more bumper primers. Inanother embodiment, the one-step RT-SDA process utilizes a first reverseand optionally one or more bumper primers. Either DNA-dependent DNApolymerase or reverse transcriptase allows for the extension of the cDNAamplified products. In yet another embodiment of the single-stepprocess, a reverse transcriptase enzyme is used to extend one or more ofthe reverse primers and synthesize cDNA from the RNA template. One ofordinary skill in the art will recognize certain conventional reversetranscriptase enzymes (i.e., AMV, MMLV, Superscript II™) that may beemployed in the methods of the present invention.

The foregoing description of the one-step RT-SDA reaction uses SDAamplification primers and bumper primers as an illustrative example. Asdescribed in U.S. Pat. No. 5,916,779, however, the reverse transcriptaseis capable of performing strand displacement with either SDA primers orreverse transcription primers. Reverse transcription primers may,therefore, also be present for use by the reverse transcriptase in thereverse transcription portion of the reaction. The downstream reversetranscription primer functions as a reverse transcription primer. Theupstream reverse transcription primer is similar to an SDA bumperprimer, as its extension serves to displace the downstream reversetranscription primer extension product (the cDNA).

Alternatively, the RT-SDA may be a two-step amplification process inwhich reverse transcription is followed by SDA in discrete steps.Accordingly, a reverse transcription primer is present in the first,reverse transcription step of the reaction. The cDNA is then separatedfrom the RNA template prior to the second, amplification step. Thereaction is either heated to separate the DNA:RNA hybrid, or the twostrands are separated through chemical or enzymatic means. For example,but not by way of limitation, RNase H or RNase H activity may be used todegrade the RNA strand and thereby create a single strand of DNA. Also,separation of the hybrid can be achieved by the use of a polymerase thatlacks 5′→3′ activity and displaces one strand from another. SDA primersare added in the second step of the reaction, and SDA amplificationproceeds to provide detectable amplification products.

In one embodiment of the two-step process, the reverse primer is an SDAprimer, and RNase H activity is endogenous to the reverse transcriptaseenzyme. Additionally, the reverse primer may be a bumper primer or arandomly generated DNA sequence. In a further embodiment of the presentinvention, two-step RT-SDA process is performed using an SDA primer andone or more bumper primers for the reverse transcription reaction.Forward primers and other reaction components necessary foramplification and detection, such as SDA enzymes, deoxyribonucleotides,signal primers, probe(s) and buffer components, are mixed with theproducts of the RT reaction.

A thermophilic version of the SDA reaction (tSDA) has recently beendeveloped, and this version is performed at a higher, but stillconstant, temperature using thermostable polymerases and restrictionendonucleases, as described in U.S. Pat. Nos. 5,648,211 and 5,744,311,which are incorporated by reference herein. The reaction is performedessentially as conventional SDA, with substitution of a thermostablepolymerase and a thermostable restriction endonuclease. The temperatureof the reaction is adjusted to a higher temperature suitable for theselected thermophilic enzymes (typically between about 45° C. and 60°C.), and the conventional restriction endonuclease recognition/cleavagesite is replaced by the appropriate restriction endonucleaserecognition/cleavage site for the selected thermostable endonuclease.Also, in contrast to conventional SDA, the practitioner may include theenzymes in the reaction mixture prior to the initial heat denaturationstep if they are sufficiently stable at that temperature.

SDA has been adapted for amplification of nucleic acid target sequencesin situ in cells in suspension, on slides or in tissues, withsensitivity and specificity comparable to the in situ PCR. This methodis described in detail in U.S. Pat. No. 5,523,204, which is incorporatedherein by reference. SDA is gentler to the cells and tissues than is PCRbecause the SDA reaction is carried out at a constant, lowertemperature. In addition, excellent specimen morphology is preserved. Insitu amplification by SDA is compatible with immunochemical techniques,so that both amplification of target sequences and immunologicalstaining can be performed on the same specimen.

An RNA-based internal control may be incorporated in the reactionmixture that co-amplifies with the SARS-CoV target sequences of thepresent invention. The internal control is designed to verify negativeresults and identify potentially inhibitory samples. Such a control mayalso be used for the purposes of quantification in a competitive assayformat as described by Nadeau et al. Anal. Biochem. 276: 177-187 (1999).In addition, the use of dried Reverse Transcriptase enzyme may be usedin conjunction with the SDA methods described herein. The dried enzymeprovides improved workflow over use of liquid enzyme together with aprotracted shelf life.

The SDA primers, Bumper Primers and Signal Primers listed in Table 1 andTable 3 were designed for use in RT-SDA reactions in accordance with themethods of the present invention. The binding sequences are underlined.For the SDA Primers, the remaining 5′ portion of the sequence comprisesthe restriction endonuclease recognition site (RERS) required for theSDA reaction to proceed and a generic non-target-specific tail sequence;whereas, for the Signal Primers, the 5′ tail comprises a genericnon-target-specific sequence which is the same as that of thecorresponding reporter probe. It will be readily apparent that the SDAprimers may also be used as amplification primers in alternativeamplification assays. It will also be apparent that the target bindingsequences may be used alone to amplify the target in reactions that donot require specialized sequences or structures (e.g., PCR) and thatdifferent specialized sequences required by amplification reactionsother than RT-SDA may be substituted for the RERS-containing sequenceshown below (e.g., an RNA polymerase promoter). The “F” and “R” in theSDA primer name indicates “forward” and “reverse” primers, respectively,when the oligonucleotides are used in amplification reactions.

TABLE 1 Primers, Probes and Sequences for SARS-CoV Assay Region A SEQ IDNO. Oligonucleotide Length 5′-3′ Sequence BUMPER PRIMERS 1 SarArtB21 *21 CAA CGC TGA GGT GTG TAG GTG 20 pUC19 Bumper 16 AAA GGA GGG ATG TGC TPrimer AB SDA PRIMERS 2 SarAFP 41 CGA TTC CGC TCC AGA CTT CTC GGG ATACCA CGT CGC AAT GT 3 SarARP * 41 ACC GCA TCG AAT GCA TGT CTC GGG ATGAAG ACC AGT AAT GA SIGNAL PRIMERS 4 SarAAd-TBD16 43 ACG TTA GCC ACC ATACGG AT GTC CAG TTA CAT TTT CTG CTT G 5 SarAAd-MPC 43 ACG TTA GCC ACC ATACTT GA GTC CAG TTA CAT TTT CTG CTT G TARGET REGION 6 Assay Region A 118ATA CCA CGT CGC AAT GTG GCT ACA TTA Consensus CAA GCA GAA AAT GTA ACTGGA CTT TTT DNA Target AAG GAC TGT AGT AAG ATC ATT ACT GGT Sequence CTTCAT CCT ACA CAG GCA CCT ACA CAC CTC AGC GTT G 7 Assay Region A 118 AUACCA CGU CGC AAU GUG GCU ACA UUA Consensus CAA GCA GAA AAU GUA ACU GGACUU RNA Transcript UUU AAG GAC UGU AGU AAG AUC AUU Sequence ACU GGU CUUCAU CCU ACA CAG GCA CCU ACA CAC CUC AGC GUU G Primer targethybridization regions are underlined BsoBI sites are italicizedMutations in the Internal Amplification Control relative to the nativeSARS-CoV consensus sequence are in lower case * May be used to primereverse transcription

TABLE 2 Reporter Probes for use with SARS-CoV Assays A and B SEQ ID NO.Oligonucleotide Length 5′-3′ Sequence REPORTER PROBE SET A 8 TBD16 (D/R)28 (DABCYL) - TCC CGA GT - (ROX) - ACG TTA GCC ACC ATA CGG AT 9 AltD8(F/D) 28 (FAM)-ACC CGA GT - (DABCYL)- AGC TAT CCG CCA TAA GCC ATREPORTER PROBE SET B 10 MPC (D/R) 29 (DABCYL) - TCC CCG AGT - (ROX) -ACG TTA GCC ACC ATA CTT GA 11 MPC2 (F/D) 29 (FAM) - TCC CCG AGT -(DABCYL) - ACT GAT CCG CAC TAA CGA CT Regions that hybridize to thecomplement of the Signal Primers are underlined (see U.S. Pat. Nos.6,316,200; 6,743,582; 6,656,680) BsoBI sites are italicized ROX:Rhodamine FAM: Fluorescein

TABLE 3 Primers, Probes and Sequences for SARS-CoV Assay Region B SEQ IDNO. Oligonucleotide Length 5′-3′ Sequence BUMPER PRIMERS 12 SarBrtB17 *17 ATA TTA TGC CAG CCA CC 13 SarBrtB19 * 19 ATA TTA TGC CAG CCA CCG TSDA PRIMERS 14 SarBFP 43 CGT AAT CCG CTC CAG ACT TCT CGG GAA TAG ACA GTT TCA TCA G 15 SarBRP * 40 ACC GCA TCG AAT GCA TGT CTCGGG TTC CAA TTA CCA CAG T SIGNAL PRIMERS 16 SarBAd-TBD16 40 ACG TTA GCCACC ATA CGG ATT GAA GTC AAT AGC CGC CAC T 17 SarBAd-MPC 40 ACG TTA GCCACC ATA CTT GAT TGA AGT CAA TAG CCG CCA CT TARGET REGION 18 Assay RegionB 101 AAT AGA CAG TTT CAT CAG Consensus AAA TTA TTG AAG TCA ATA DNATarget Sequence GCC GCC ACT AGA GGA GCT ACT GTG GTA ATT GGA ACA AGC AAGTTT TAC GGT GGC TGG CAT AAT AT 19 Assay Region B 101 AAU AGA CAG UUU CAUCAG Consensus AAA UUA UUG AAG UCA RNA Transcript AUA GCC GCC ACU AGA GGASequence GCU ACU GUG GUA AUU GGA ACA AGC AAG UUU UAC GGU GGC UGG CAU AAUAU Primer target hybridization regions are underlined BsoBI sites areitalicized * May be used to prime reverse transcription

Following target amplification, the nucleic acids produced by themethods of the present invention may be detected by any of the methodsknown in the art for detection of specific nucleic acid sequences. Forexample, but not by way of limitation, a variety of detection methodsfor SDA may be used. Several methods for labeling SDA products arediscussed in U.S. Pat. No. 6,316,200, the entire teaching of which isherein incorporated by reference. For example, but not by way oflimitation, amplification products may be detected by specifichybridization to an oligonucleotide detector probe. The detector probeis a short oligonucleotide that includes a detectable label, i.e., amoiety that generates or can be made to generate a detectable signal.The label may be incorporated into the oligonucleotide probe by nicktranslation, end-labeling or during chemical synthesis of the probe.Many directly and indirectly detectable labels are known in the art foruse with oligonucleotide probes. Directly detectable labels includethose labels that do not require further reaction to be made detectable,e.g., radioisotopes, fluorescent moieties and dyes. Indirectlydetectable labels include those labels that must be reacted withadditional reagents to be made detectable, e.g., enzymes capable ofproducing a colored reaction product (e.g., alkaline phosphatase (AP) orhorseradish peroxidase), biotin, avidin, digoxigenin, antigens, haptensor fluorochromes. The signal from enzyme labels is generally developedby reacting the enzyme with its substrate and any additional reagentsrequired to generate a colored enzymatic reaction product. Biotin (oravidin) labels may be detected by binding to labeled avidin (or labeledbiotin) or labeled anti-biotin (or labeled anti-avidin) antibodies.Digoxigenin and hapten labels are usually detected by specific bindingto a labeled anti-digoxigenin (anti-dig) or anti-hapten antibody. Ingeneral, the detector probe will be selected such that it hybridizes toa nucleotide sequence in the amplicon that is between the binding sitesof the two amplification primers. A detector probe may also have thesame nucleotide sequence as either of the amplification primers. Methodsfor detection in vitro and in situ by hybridization to a detector probeare known in the art.

Alternatively, the amplification products of the present invention maybe detected by extension of a detector primer as described by Walker, etal., Nuc. Acids Res., supra. In the detector primer extension method, anoligonucleotide primer comprising a detectable label is hybridized tothe amplification products and extended by addition of polymerase. Fordetection, the primer may be 5′ end-labeled, for example, using ³²P or afluorescent label. Alternatively, extension of the hybridized primer mayincorporate a dNTP analog comprising a directly or indirectly detectablelabel. For example, but not by way of limitation, extension of theprimer may incorporate a dig-derivatized dNTP, which is then detectedafter extension by reaction with AP anti-dig and a suitable APsubstrate. The primer to be extended may either be the same as anamplification primer or it may be a different primer that hybridizes toa nucleotide sequence in the amplicon that is between the binding sitesof the amplification primers.

The detectable label may also be incorporated directly into ampliconsduring target sequence amplification.

In another embodiment of the invention, RT-SDA products are detected bythe methods described in U.S. Pat. No. 6,316,200 that utilize anunlabelled signal primer comprising a 5′ adapter sequence. The 3′ end ofa reporter probe hybridizes to the complement of the 5′ end of thesignal primer, producing a 5′ overhang. Polymerase fills in the overhangand synthesis of the complement of the reporter probe tail is detected,either directly or indirectly, as an indication of the presence oftarget. This method utilizes fluorescent energy transfer (FET) ratherthan the direct detection of fluorescent intensity for detection ofhybridization. FET allows for real-time detection of SDA products.

The Signal Primers and Reporter Probes listed in Table 1 through Table 3were designed for real-time detection of amplification products usingthe reverse transcriptase products. The structure and use of suchprimers and probes is described, for example, but not by way oflimitation, in U.S. Pat. Nos. 5,547,861, 5,928,869, 6,316,200, 6,656,680and 6,743,582 each of which is incorporated herein by reference. Thehybridization sequences in Tables 1 through Table 3 are underlined. Theremaining portions of the Reporter Probe sequences form structures thatare typically labeled to facilitate detection of amplification productsas is known in the art. It will be readily apparent that the targetsequence may be used alone for direct hybridization (typically linked toa detectable label) and that other directly and indirectly labels may besubstituted for the hairpin as is known in U.S. Pat. No. 5,935,791;5,846,726; 5,691,145; 5,550,025; and 5,593,867, the contents of each ofwhich is incorporated herein by reference.

Because the target binding sequence confers target specificity on theprimer or probe, it should be understood that the target bindingsequences exemplified above for use as particular components of aspecified reaction may also be used in a variety of other ways for thedetection of SARS-CoV replicase nucleic acid. For example, but not byway of limitation, the target binding sequences of the invention may beused as hybridization probes for direct detection of SARS-CoV, eitherwithout amplification or as a post-amplification assay. Suchhybridization methods are well-known in the art and typically employ adetectable label associated with or linked to the target bindingsequence to facilitate detection of hybridization. Further, essentiallyall of the target binding sequences set forth above may be used asamplification primers in amplification reaction which do not requireadditional specialized sequences (such as PCR) or appended to theappropriate specialized for use in 3SR, NASBA, transcription-based orany other primer extension amplification reactions. For detection ofamplification products, amplification primers comprising the targetbinding sequences disclosed herein may be labeled as is known in theart. As an alternative, labeled detector primers comprising thedisclosed target binding sequences may be used in conjunction withamplification primers as described in U.S. Pat. Nos. 5,547,861;5,928,869; 5,593,867; 5,550,025; 5,935,791; 5,888,739; and 5,846,726,each of which is incorporated by reference herein, for real-timehomogenous detection of amplification. Such detector primers maycomprise a directly or indirectly detectable sequence that does notinitially hybridize to the target but which facilitates detection of thedetector primer once it has hybridized to the target and has beenextended. For example, such detectable sequences may be sequences thatform a secondary structure, sequences that contain a restriction site,or linear sequences that are detected by hybridization of theircomplements to a labeled oligonucleotide (sometimes referred to as areporter probe) as is known in the art. Alternatively, the amplificationproducts may be detected post-amplification by hybridization of a probeselected from any of the target binding sequences disclosed herein thatfall between a selected set of amplification primers.

It is to be understood that an oligonucleotide according to the presentinvention that consists of a target binding sequence and, optionally,either a sequence required for a selected amplification reaction or asequence required for a selected detection reaction may also includecertain other sequences that serve as spacers, linkers, sequences forlabeling or binding of an enzyme, etc. Such additional sequences aretypically known to be necessary to obtain optimum function of theoligonucleotide in the selected reaction and are intended to be includedby the term “consisting of.”

The present invention also relates to nucleic acid molecules thathybridize under high stringency hybridization conditions (i.e., forselective hybridization) to the nucleotide sequence described herein.“Stringency conditions” refer to the incubation and wash conditions(e.g., temperature, buffer concentration) that determine hybridizationof a first nucleic acid to a second nucleic acids The first and secondnucleic acids may be perfectly (100%) complementary, or may be less thanperfect (i.e., 70%, 50%, etc.). For example, certain high stringencyconditions can be used that distinguish perfectly complementary nucleicacids from those of less complementarity. “High stringency conditions,”“moderate stringency conditions” and “low stringency conditions” fornucleic acid hybridizations are explained on pages 2.10.1-2.10.16 andpages 6.3.1-6.3.6 in Current Protocols in Molecular Biology (Ausubel, F.M. et al., John Wiley & Sons (1998), the entire teachings of which areincorporated by reference herein).

Another aspect of the present invention pertains to host cells intowhich a vector of the invention has been introduced. A host cell can beany prokaryotic or eukaryotic cell. For example, the nucleic acidmolecules of the present invention can be expressed in bacterial cells,insect cells, yeast or mammalian cells. Such suitable host cells areknown to those skilled in the art.

The invention also provides a pack or kit comprising one or morecontainers filled with one or more of the ingredients used in thepresent invention. Optionally associated with such container(s) can be anotice in the form prescribed by a governmental agency regulating themanufacture, use or sale of pharmaceuticals or biological products,which notice reflects approval by the agency for manufacture, use orsale for administration. The pack or kit can be a single unit use of thecompositions or it can be a plurality of uses. In particular, the agentscan be separated, mixed together in any combination, or present in asingle vial

The following prophetic examples are provided to illustrate certainembodiments of the invention, but are not intended to limit theinvention.

SARS Assay System A Example: RT-SDA for the Detection of SARS-CoV RNA.

The following example illustrates the use of the disclosed primers andreporter Probes for the detection of SARS-CoV RNA in clinical samplesfrom patients suspected of infection.

Clinical specimens such as stools, throat swabs and nasopharyngealaspirates are processed using a QIAGEN QIAamp Viral RNA Mini kitaccording to the manufacturer's instructions with the addition of anon-column DNase treatment to remove contaminating DNA. For stoolspecimens, an additional pre-processing step is included to removeparticulate matter prior to loading on the QIAGEN columns. Stools arediluted 1:10 with 0.89% saline and centrifuged for 20 min. at 4,000×g.The supernatant is then decanted and passed through a 0.22 μm filter toremove particulate debris.

One hundred and forty microliters of the clinical sample or stoolfiltrate are processed through a QIAamp column that is treated withDNase to digest contaminating non-specific DNA bound to the columnmatrix. After washing to remove the DNase, purified RNA is eluted in avolume of 80 mL water. Thirty microliters of eluate are added to aPriming Microwell containing dried primers, Reporter Probes andnucleotides, followed by 20 μL of Reverse Transcription Buffercontaining RNase inhibitor, AMV-RT enzyme and RNA transcripts of anInternal Amplification Control sequence. Final reaction conditions forreverse transcription are as follows: 1500 μM dC_(s)TP; 300 μM each ofDATP, dGTP and dTTP; 5 mM magnesium acetate; 1500 nM bumper primerSarArtB21 (SEQ ID NO.: 1); 300 nM SDA Primer SarARP (SEQ ID NO.: 3);1500 nM SDA Primer SarAFP (SEQ ID NO.: 2); 750 nM Signal PrimerSarAAd-MPC (SEQ ID NO.: 5); 600 nM IAC Signal Primer; 1200 nM ReporterProbe MPC D/R (SEQ ID NO.: 10); 900 nM Reporter Probe MPC2 F/D (SEQ IDNO.: 11); 1000 copies of IAC transcript; 5% DMSO; 5% glycerol; 43.5 mMK_(i)PO₄; 25 mM KOH; 120 mM bicine; 40 U RNase inhibitor; 10 U AMV-RT.Rehydrated microwells are then incubated at 48° C. for 20 min. beforeaddition of 100 μL of SDA Buffer and transfer to a 72° C. heat block. Atthe same time, Amplification Microwells containing dried SDA enzymes(Bst polymerase and BsoBI restriction enzyme) are pre-warmed at 54° C.After a 10 min. incubation, 100 μL of sample are transferred from thePriming Microwells to the Amplification Microwells, which are thensealed and incubated in a BD ProbeTec ET reader at 52.5° C. Finalreaction conditions for SDA are as follows: 500 μM dC_(s)TP; 10 μM eachof dATP, dGTP and dTTP; 5.7 mM magnesium acetate; 1500 nM Bumper PrimerSarArtB21 (SEQ ID NO.: 1); 100 nM SDA Primer SarARP (SEQ ID NO.: 3); 500nM SDA Primer SarAFP (SEQ ID NO.: 2); 250 nM Signal Primer SarAAd-MPC(SEQ ID NO.: 5); 200 nM IAC Signal Primer; 400 nM Reporter Probe MPC D/R(SEQ ID NO.: 10); 300 nM IAC Reporter Probe MPC2 F/D (SEQ ID NO.: 11);12.5% DMSO; 1.67% glycerol; 24.5 mM K_(i)PO₄; 82 mM KOH; 143 mM bicine;12 U Bst polymerase; 45 U BsoBI restriction enzyme.

During the course of a 1 hour incubation, fluorescent readings are takenevery minute in both optical channels of the BD ProbeTec ET instrumentand results are reported in terms of the PAT scores for the SARS-CoVtarget and IAC. Reactions in which the fluorescent readings neverachieve the predetermined threshold of fluorescence are assigned a PATscore of 0. Reactions that yielded ROX PAT scores >0, corresponding tothe MPC D/R Reporter Probe (SEQ ID NO.: 10), are considered positive forSARS-CoV, while reactions that yield FAM PAT scores >0, corresponding tothe IAC Reporter Probe MPC2 F/D (SEQ ID NO.: 11), are consideredpositive for IAC. Those in which neither the FAM nor ROX signals achievetheir respective thresholds (PAT scores=0) are considered indeterminate.External positive and negative controls are included in each assay runto verify performance. These controls are required to yield the positiveand negative correct results respectively in order for the results frompatient specimens to be reported by the instrument.

Anticipated Results and Conclusions

Specimens from infected patients that contain SARS-CoV in sufficientquantity to be above the limit of detection of the assay would yieldpositive results (i.e., ROX PAT scores>0). Specimens from uninfectedpatients or from those whose clinical load is below the analyticalsensitivity of the assay would yield negative results (i.e., ROX PATscore=0). Contamination of reagents with RNase or procedural error wouldbe indicated by a failure of the IAC to amplify (i.e., FAM PAT score=0).A summary of possible results is presented in Table 4.

TABLE 4 Summary of possible result outcomes for the BD ProbeTec ETSARS-CoV assay PAT Score SARS-CoV Target IAC (ROX) (FAM) ReportedResult >0 Any Positive for SARS-CoV 0  0 Indeterminate 0 >0 Negative forSARS-CoV or virus present below the analytical sensitivity of the assay

SARS Assay System B Example: RT-SDA for the Detection of SARS-CoV RNA

The following example illustrates the use of the disclosed primers andreporter Probes for the detection of SARS-CoV RNA in clinical specimens.

Clinical specimens such as stool samples, throat swabs andnasopharyngeal aspirates are processed using a QIAGEN QIAamp Viral RNAMini kit according to the manufacturer's instructions with the additionof an on-column DNase treatment to remove contaminating DNA. For stoolspecimens, an additional pre-processing step is included to removeparticulate matter prior to loading on the QIAGEN columns. Stools arediluted 1:10 with 0.89% saline and centrifuged for 20 min. at 4,000×g.The supernatant is then decanted and passed through a 0.22 μm filter toremove particulate debris.

One hundred and forty microliters of the sample or stool filtrate areprocessed through a QIAamp column that is treated with DNase to digestcontaminating non-specific DNA bound to the column matrix. After washingto remove the DNase, purified RNA is eluted in a volume of 80 μL water.Thirty microliters of eluate are added to a Priming Microwell containingdried primers, Reporter Probes and nucleotides, followed by 20 μL ofReverse Transcription Buffer containing RNase inhibitor, AMV-RT enzymeand RNA transcripts of an Internal Amplification Control sequence. Finalreaction conditions for reverse transcription are as follows: 1500 μMdC_(s)TP; 300 μM each of dATP, dGTP and dTTP; 5 mM magnesium acetate;1500 nM Bumper Primer SarBrtB19 (SEQ ID NO.: 13); 1500 nM SDA PrimerSarBRP (SEQ ID NO.: 15); 300 nM SDA Primer SarBFP (SEQ ID NO.: 14); 750nM Signal Primer SarBAd-MPC (SEQ ID NO.: 17); 600 nM IAC Signal Primer;1200 nM Reporter Probe MPC D/R (SEQ ID NO.: 10); 900 nM IAC ReporterProbe MPC2 F/D (SEQ ID NO.: 11); 1000 copies of IAC transcript; 5% DMSO;5% glycerol; 43.5 mM K_(i)PO₄; 25 mM KOH; 120 mM bicine; 40 U RNaseinhibitor; 10 U AMV-RT. Rehydrated microwells are then incubated at 48°C. for 20 min. before addition of 100 μL of SDA Buffer and transfer to a72° C. heat block. At the same time, Amplification Microwells containingdried SDA enzymes (Bst polymerase and BsoBI restriction enzyme) areplaced at 52° C. After a 10 min. incubation, 100 μL of sample aretransferred from the Priming Microwells to the Amplification Microwells,which are then sealed and incubated in a BD ProbeTec ET reader at 52.5°C. Final reaction conditions for SDA are as follows: 500 μM dC_(s)TP;100 μM each of dATP, dGTP and dTTP; 5.7 mM magnesium acetate; 500 nMBumper Primer SarArtB19 (SEQ ID NO.: 13); 500 nM SDA Primer SarBRP (SEQID NO.: 15); 100 nM SDA Primer SarBFP (SEQ ID NO.: 14); 250 nM SignalPrimer SarBAd-MPC (SEQ ID NO.: 17); 200 nM IAC Signal Primer; 400 nMReporter Probe MPC D/R (SEQ ID NO.: 10); 300 nM IAC Reporter Probe MPC2F/D (SEQ ID NO.: 11); 12.5% DMSO; 1.67% glycerol; 24.5 mM K_(i)PO₄; 82mM KOH; 143 mM bicine; 12 U Bst polymerase; 45 U BsoBI restrictionenzyme.

During the course of a 1 hour incubation, fluorescent readings are takenevery minute in both optical channels of the BD ProbeTec ET instrumentand results are reported in terms of the PAT scores for the SARS-CoVtarget and IAC. Reactions in which the fluorescent readings neverachieve the predetermined threshold of fluorescence are assigned a PATscore of 0. Reactions that yielded ROX PAT scores >0, corresponding tothe MPC D/R Reporter Probe (SEQ ID NO.: 10), are considered positive forSARS-CoV, while reactions that yield FAM PAT scores>0, corresponding tothe IAC Reporter Probe MPC2 F/D (SEQ ID NO.: 11), are consideredpositive for IAC. Those in which neither the FAM nor ROX signals achievetheir respective thresholds (PAT scores=0) are considered indeterminate.External positive and negative controls are included in each assay runto verify performance. These controls are required to yield the positiveand negative correct results respectively in order for the results frompatient specimens to be reported by the instrument.

Anticipated Results and Conclusions

Specimens from infected patients that contain SARS-CoV in sufficientquantity to be above the limit of detection of the assay would yieldpositive results (i.e., ROX PAT scores>0). Specimens from uninfectedpatients or from those whose clinical load is below the analyticalsensitivity of the assay would yield negative results (i.e., ROX PATscore=0). Contamination of reagents with RNase or procedural error wouldbe indicated by a failure of the IAC to amplify (i.e., FAM PAT score=0).A summary of possible results is presented in Table 5.

TABLE 5 Summary of possible result outcomes for the BD ProbeTec ETSARS-CoV assay PAT Score SARS-CoV Target IAC (ROX) (FAM) ReportedResult >0 Any Positive for SARS-CoV 0 0 Indeterminate 0 >0 Negative forSARS-CoV or virus present below the analytical sensitivity of the assay

The following experimental examples are provided to illustrate certainembodiments of the invention, but are not intended to limit theinvention.

SARS Assay System A Examples EXAMPLE 1 DNA Amplification UsingSARS-CoV-Specific Primers Part A:

The ability of the disclosed combination of primers and probes toamplify SARS-CoV nucleic acid was demonstrated using a plasmid DNA cloneof the target sequence corresponding to nucleotides 17936-18024 ofSARS-CoV strain BJ03 (GenBank Accession No. AY278490). Linearizedplasmid DNA was quantified using PicoGreen® dsDNA Quantitation Reagent(Molecular Probes, Inc., Eugene, Oreg.) and diluted to a workingconcentration with water containing 7 ng/mL salmon sperm DNA. Fourreplicate SDA reactions were run at each of six target levels, includingnegative controls that contained water in place of target DNA.

In brief, DNA target was added to SDA Buffer and denatured by heating ina boiling water bath for 5 min. One hundred and ten microliters of thedenatured sample was then added to Priming Microwells containing 40 μLof a solution of SDA Primers, Reporter Probe and nucleotides. Followingan incubation at ambient temperature for 20 min., the Priming Microwellswere transferred to a heat block at 72° C., while correspondingAmplification Microwells containing dried Bst polymerase and BsoBIrestriction enzyme were pre-warmed at 54° C. After 10 min. incubation,100 μL of the priming mixture were transferred from the Priming to theAmplification Microwells, which were then sealed and loaded into a BDProbeTec ET reader set at 52.5° C. Fluorescent signals were monitoredover the course of 1 hour and analyzed using the Passes After Threshold(PAT) algorithm developed for this instrument. (Wolfe D M, Wang S S,Thornton K, Kuhn A M, Nadeau J G, Hellyer T J. Homogeneous stranddisplacement amplification. In: DNA amplification—current technologiesand applications, Demidov V V and Broude N E (Eds.), Horizon Bioscience,Wymondham, UK.) The PAT scores represent the number of instrument passesremaining after the fluorescent readings achieve a pre-defined thresholdvalue. Final SDA reaction conditions were as follows: 50 nM pUC19-basedBumper Primer AB (SEQ ID NO.: 20); 100 nM SDA Primer SarARP (SEQ ID NO.:3); 500 nM SDA Primer SarAFP (SEQ ID NO.: 2); 250 nM Signal PrimerSarAAd-TBD16 (SEQ ID NO.: 4); 500 nM Reporter Probe TBD16 D/R (SEQ IDNO.: 8); 500 μM deoxycytidine 5′-O-(1-Thiotriphosphate), S-isomer(dC_(s)TP); 100 μM each of dATP, dGTP and dTTP; 12.5% DMSO; 25 mMK_(i)PO₄; 82 mM KOH; 143 mM bicine; 12 U Bst polymerase; 30 U BsoBIrestriction enzyme; 5 mM magnesium acetate.

RESULTS AND CONCLUSIONS

Positive results were obtained with as little 25 copies of the targetplasmid per reaction while no false-positive results were observed inany of the negative controls (Table 6). These data demonstrate that thedisclosed combination of primers and Reporter Probe is capable ofdetecting a SARS-CoV-specific nucleic acid target sequence with a highdegree of analytical sensitivity.

TABLE 6 Amplification and detection of a SARS-CoV-specific targetsequence Target Level Per PAT Score Reaction A B C D Mean 10000 52 51 4951 51 1000 52 51 50 51 51 500 50 47 44 50 48 100 50 49 50 49 49 50 37 00 43 20 25 35 47 0 47 32 0 0 0 0 0 0 PAT scores: 0 = Negative; >0 =Positive

Part B:

A second experiment was conducted to demonstrate the analyticalsensitivity of the disclosed primers for the detection ofSARS-CoV-specific nucleic acid. In contrast to the previous experiment,Reporter Probe MPC D/R (SEQ ID NO.: 10) was used together with SignalPrimer SarAAd-MPC (SEQ ID NO.: 5).

Briefly, DNA target was added to SDA Buffer and denatured by heating ina boiling water bath for 5 min. One hundred and ten microliters of thedenatured sample was then added to Priming Microwells containing 40 μLof a solution of SDA Primers, Reporter Probe and nucleotides. ThePriming Microwells were allowed to sit for 20 min. at ambienttemperature, before being transferred to a heat block at 72° C. At thesame time, corresponding Amplification Microwells containing dried Bstpolymerase and BsoBI restriction enzyme were pre-warmed at 54° C.Following a 10 min. incubation, 100 μL of the priming mixture weretransferred from the Priming to the Amplification Microwells, which werethen sealed and placed at 52.5° C. in a BD ProbeTec ET reader.Fluorescent signals were monitored over the course of 1 hour andanalyzed using the PAT algorithm developed for this instrument. The PATscores represent the number of instrument passes remaining after thefluorescent readings achieve a pre-defined threshold value. Final SDAreaction conditions were as follows: 50 nM pUC19-based Bumper Primer AB(SEQ ID NO.: 20); 100 nM SDA Primer SarARP (SEQ ID NO.: 3); 500 nM SDAPrimer SarAFP (SEQ ID NO.: 2); 250 nM Signal Primer SarAAd-MPC (SEQ IDNO.: 5); 500 nM Reporter Probe MPC D/R (SEQ ID NO.: 10); 500 μMdC_(s)TP; 100 μM each of dATP, dGTP and dTTP; 12.5% DMSO; 25 mMK_(i)PO₄; 82 mM KOH; 143 mM bicine; 12 U Bst polymerase; 30 U BsoBIrestriction enzyme; 5 mM magnesium acetate.

RESULTS AND CONCLUSIONS

Results are summarized in Table 7. All reactions containing 100 copiesof plasmid DNA were positive. In contrast, none of the reactionscontaining water in place of plasmid DNA yielded positive results,thereby demonstrating the analytical sensitivity and specificity of thedisclosed of primers and Reporter Probe combination for the detection ofthe SARS-CoV-specific nucleic acid target sequence.

TABLE 7 Amplification and detection of a SARS-CoV-specific targetsequence using MPC D/R Reporter Probe PAT Score 100 Targets PerReplicate Reaction Negative Control A 47.8 0 B 47.9 0 C 47.7 0 D 48.0 0E 45.9 0 F 46.0 0 G 49.2 0 H 47.6 0 Mean 47.5 0 PAT scores: 0 =Negative; >0 = Positive

EXAMPLE 2 Analytical Specificity

The analytical specificity of the disclosed primers and probes wasverified by testing a panel of 43 bacteria and fungi that are likely tobe found in respiratory and/or gastrointestinal specimens. Because allthese organisms have genomes comprised of DNA rather than RNA, noreverse transcription step was included in these reactions. A suspensionof each organism was prepared in Phosphate-Buffered Saline containingBovine Serum Albumin (PBS/BSA) at a concentration of approximately10⁷-10⁸ cells/mL. Fifteen microliters of each suspension were mixed with150 μL SDA Buffer and heated in a boiling water bath for 5 min. to lysethe organisms and denature the DNA. After cooling to room temperature,110 μL of denatured sample were added to a Priming Microwell containingcontaining 40 μL of a solution of SDA Primers, Reporter Probe andnucleotides. The Priming Microwells were incubated at ambienttemperature for 20 min. and then transferred to a heat block at 72° C.,while corresponding Amplification Microwells were pre-warmed at 54° C.After 10 min., 100 μL of the priming mixture were transferred from thePriming to the Amplification Microwells, which were then sealed andloaded into a BD ProbeTec ET reader set at 52.5° C. Fluorescence wasmonitored over the course of 1 hour and analyzed using the PAT algorithmdeveloped for this instrument. Final SDA conditions were as follows: 50nM pUC19-based Bumper Primer AB (SEQ ID NO.: 20); 100 nM SDA PrimerSarARP (SEQ ID NO.: 3); 500 nM SDA Primer SarAFP (SEQ ID NO.: 2); 250 nMSignal Primer SarAAd-TBD16 (SEQ ID NO.: 4); 500 nM Reporter Probe TBD16D/R (SEQ ID NO.: 8); 500 μM dC_(s)TP; 100 μM each of dATP, dGTP anddTTP; 12.5% DMSO; 25 mM K_(i)PO₄; 82 mM KOH; 143 mM bicine; 12 U Bstpolymerase; 30 U BsoBI restriction enzyme; 5 mM magnesium acetate.

RESULTS AND CONCLUSIONS

Results are summarized in Table 8. No positive results were obtainedexcept from a plasmid clone of the SARS-CoV target sequence that was runas a positive control, thereby demonstrating the specificity of thedisclosed primers and Reporter Probe for the detection of SARS-CoV.

TABLE 8 Panel of bacteria and fungi tested with the BD ProbeTec ETSARS-CoV assay PAT Species Strain Score Result Acinetobactercalcoaceticus BD 13339 0 Negative Actinomyces israelii ATCC 10049 0Negative Aeromonas hydrophila ATCC 7966 0 Negative Alcaligenes faecalisATCC 8750 0 Negative Bacteroides fragilis ATCC 25285 0 NegativeBordetella pertussis ATCC 9797 0 Negative Candida albicans ATCC 44808 0Negative Chlamydophila pneumoniae AR-39 0 Negative Citrobacter freundiiATCC 8090 0 Negative Corynebacterium diphtheriae ATCC 11913 0 NegativeCorynebacterium jeikeium ATCC 43734 0 Negative Cryptococcus neoformansATCC 36556 0 Negative Edwardsiella tarda ATCC 15469 0 Negative Eikenellacorrodens ATCC 23834 0 Negative Enterobacter aerogenes ATCC 13048 0Negative Enterococcus faecalis ATCC 29212 0 Negative Escherichia coliATCC 11775 0 Negative Fusobacterium nucleatum ATCC 25586 0 NegativeHaemophilus influenzae ATCC 33533 0 Negative Haemophilus parainfluenzaeATCC 7901 0 Negative Kingella kingae ATCC 23330 0 Negative Klebsiellapneumoniae subsp. ATCC 13883 0 Negative pneumoniae Lactobacillusacidophilus ATCC 4356 0 Negative Legionella pneumophila ATCC 33152 0Negative Morganella morganii ATCC 25830 0 Negative Neisseria mucosa ATCC19696 0 Negative Peptostreptococcus anaerobius ATCC 27337 0 NegativePlesiomonas shigelloides ATCC 14029 0 Negative Porphyromonasasaccharolytica ATCC 25260 0 Negative Proteus mirabilis ATCC 29906 0Negative Pseudomonas aeruginosa ATCC 27853 0 Negative Serratiamarcescens ATCC 8100 0 Negative Staphylococcus aureus ATCC 12598 0Negative Staphylococcus epidermidis ATCC E155 0 NegativeStenotrophomonas maltophila ATCC 13637 0 Negative Streptococcus mutansATCC 25175 0 Negative Streptococcus pneumoniae ATCC 6303 0 NegativeStreptococcus pyogenes ATCC 19615 0 Negative Veillonella parvula ATCC10790 0 Negative Yersinia enterolitica ATCC 27729 0 Negative Yersiniaruckeri Not known 0 Negative SARS-CoV Positive Control Not 44.7 PositiveApplicable SARS-CoV Positive Control Not 41.1 Positive ApplicableSARS-CoV Positive Control Not 23.7 Positive Applicable SARS-CoV PositiveControl Not 43.3 Positive Applicable SARS-CoV Negative Control Not 0Negative Applicable SARS-CoV Negative Control Not 0 Negative ApplicableSARS-CoV Negative Control Not 0 Negative Applicable SARS-CoV NegativeControl Not 0 Negative Applicable BD: BD Diagnostics ATCC: American TypeCulture Collection PAT scores >0 were considered positive

SARS Assay System B Examples EXAMPLE 1 DNA Amplification UsingSARS-CoV-Specific Primers

The ability of the disclosed combination of primers and probes toamplify SARS-CoV nucleic acid was demonstrated using a plasmid DNA cloneof the target sequence corresponding to nucleotides 15068-15138 ofSARS-CoV strain BJ03 (GenBank Accession No. AY278490). Linearizedplasmid DNA was quantified using PicoGreen dsDNA Quantitation Reagent(Molecular Probes, Inc., Eugene, Oreg.) and diluted to a workingconcentration with water containing 7 ng/μL salmon sperm DNA. Eightreplicate SDA reactions were run at each of three target levels,including negative controls that contained water in place of target DNA.

In brief, DNA target was added to SDA Buffer and denatured for byheating in a boiling water bath for 5 min. One hundred and fiftymicroliters of the denatured sample was then added to Priming Microwellscontaining dried SDA Primers, Reporter Probe and nucleotides. Followingan incubation at ambient temperature for 20 min., the Priming Microwellswere transferred to a heat block at 72° C., while correspondingAmplification Microwells containing dried Bst polymerase and BsoBIrestriction enzyme were pre-warmed at 54° C. After 10 min., 100 μL ofthe priming mixture were transferred from the Priming to theAmplification Microwells, which were then sealed and loaded into a BDProbeTec ET reader set at 52.5° C. Fluorescent signals were monitoredover the course of 1 hour and analyzed using the PAT algorithm developedfor this instrument. The PAT scores represent the number of instrumentpasses remaining after the fluorescent readings achieve a pre-definedthreshold value. Final SDA reaction conditions were as follows: 50 nMpUC19-based Bumper Primer AB (SEQ ID NO.: 20); 500 nM SDA Primer SarBRP(SEQ ID NO.: 15); 100 nM SDA Primer SarBFP (SEQ ID NO.: 14); 250 nMSignal Primer SarBAd-MPC (SEQ ID NO.: 4); 300 nM Reporter Probe MPC D/R(SEQ ID NO.: 8); 500 mM deoxycytidine 5′-O-(1-Thiotriphosphate),S-isomer (dC₈TP); 100 μM each of dATP, dGTP and dTTP; 12.5% DMSO; 25 mMK_(i)PO₄; 82 mM KOH; 143 mM bicine; 12 U Bst polymerase; 30 U BsoBIrestriction enzyme; 5 mM magnesium acetate.

RESULTS AND CONCLUSIONS

Positive results were obtained with as little 15 copies of the targetplasmid per reaction while no false-positive results were observed inany of the negative controls (Table 9). These data demonstrate that thedisclosed combination of primers and Reporter Probe is capable ofdetecting the targeted SARS-CoV-specific nucleic acid sequence with ahigh degree of analytical sensitivity.

TABLE 9 Amplification and detection of a SARS-CoV-specific targetsequence PAT Score Negative 15 Targets Per 75 Targets Per ReplicateControl Reaction Reaction A 0 42 47 B 0 42 47 C 0 46 48 D 0 48 48 E 0 4548 F 0 46 49 G 0 47 49 H 0 43 45 Mean 0 45 48 PAT scores: 0 =Negative; >0 = Positive

EXAMPLE 2 Analytical Specificity

The analytical specificity of the disclosed primers and probes wasverified by testing a panel of 43 bacteria and fungi that are likely tobe found in respiratory and/or gastrointestinal specimens. Because allthese organisms have genomes comprised of DNA rather than RNA, noreverse transcription step was included in these reactions. A suspensionof each organism was prepared in PBS/BSA at a concentration ofapproximately 10⁷-10⁸ cells/mL. Fifteen microliters of each suspensionwere mixed with 150 μL SDA Buffer and heated in a boiling water bath for5 min. to lyse the organisms and denature the DNA. After cooling to roomtemperature, 110 μL of denatured sample were added to a PrimingMicrowell containing containing 40 μL of a solution of SDA Primers,Reporter Probe and nucleotides. The Priming Microwells were allowed tosit at ambient temperature for 20 min. and then transferred to a heatblock at 72° C., while corresponding Amplification Microwells werepre-warmed at 54° C. After a 10 min. incubation, 100 μL of the primingmixture were transferred from the Priming to the AmplificationMicrowells, which were then sealed and loaded into a BD ProbeTec ETreader set at 52.5° C. Fluorescence was monitored over the course of 1hour and analyzed using the PAT algorithm developed for this instrument.Final SDA conditions were as follows: 50 nM pUC19-based Bumper Primer AB(SEQ ID NO.: 20); 500 nM SDA Primer SarBRP (SEQ ID NO.: 15); 100 nM SDAPrimer SarBFP (SEQ ID NO.: 14); 250 nM Signal Primer SarBAd-MPC (SEQ IDNO.: 17); 500 nM Reporter Probe MPC D/R (SEQ ID NO.: 10); 500 mMdC_(s)TP; 100 μM each of dATP, dGTP and dTTP; 12.5% DMSO; 25 mM KiPO4;82 mM KOH; 143 mM bicine; 12 U Bst polymerase; 30 U BsoBI restrictionenzyme; 5 mM magnesium acetate.

RESULTS AND CONCLUSIONS

As illustrated in Table 10, no positive results were obtained exceptfrom a plasmid clone of the SARS-CoV target sequence that was run as apositive control. This demonstrates the specificity of the disclosedprimers and Reporter Probe for the detection of SARS-CoV.

TABLE 10 Panel of bacteria and fungi tested with the BD ProbeTec ETSARS-CoV assay PAT Species Strain Score Result Acinetobactercalcoaceticus BD 13339 0 Negative Actinomyces israelii ATCC 10049  0*Negative Aeromonas hydrophila ATCC 7966 0 Negative Alcaligenes faecalisATCC 8750 0 Negative Bacteroides fragilis ATCC 25285 0 NegativeBlastomyces dermatitidis ATCC 4292 0 Negative Bordetella pertussis ATCC9797 0 Negative Branhamella catarrhalis ATCC 25238 0 Negative Candidaalbicans ATCC 44808 0 Negative Chlamydophila pneumoniae AR-39 0 NegativeCitrobacter freundii ATCC 8090 0 Negative Clostridium perfringens ATCC13124 0 Negative Corynebacterium diphtheriae ATCC 11913 0 NegativeCorynebacterium jeikeium ATCC 43734 0 Negative Cryptococcus neoformansATCC 36556 0 Negative Edwardsiella tarda ATCC 15469 0 Negative Eikenellacorrodens ATCC 23834 0 Negative Enterobacter aerogenes ATCC 13048 0Negative Enterococcus faecalis ATCC 29212 0 Negative Escherichia coliATCC 11775 0 Negative Fusobacterium nucleatum ATCC 25586 0 NegativeHaemophilus influenzae ATCC 33533 0 Negative Haemophilus parainfluenzaeATCC 7901 0 Negative Histoplasma capsulatum ATCC 12700 0 NegativeKingella kingae ATCC 23330 0 Negative Klebsiella pneumoniae subsp. ATCC13883 0 Negative pneumoniae Lactobacillus acidophilus ATCC 4356 0Negative Legionella pneumophila ATCC 33152 0 Negative Moraxellaosloensis ATCC 19976 0 Negative Morganella morganii ATCC 25830 0Negative Mycobacterium tuberculosis ATCC 27294 0 Negative Mycoplasmapneumoniae ATCC 29342 0 Negative Neisseria meningitides ATCC 13077 0Negative Neisseria mucosa ATCC 19696 0 Negative Peptostreptococcusanaerobius ATCC 27337 0 Negative Plesiomonas shigelloides ATCC 14029 0Negative Porphyromonas asaccharolytica ATCC 25260 0 Negative Proteusmirabilis ATCC 29906 0 Negative Providencia stuartii ATCC 35031 0Negative Pseudomonas aeruginosa ATCC 27853 0 Negative Serratiamarcescens ATCC 8100 0 Negative Salmonella cholerasuis ATCC 13076 0Negative Staphylococcus aureus ATCC 12598 0 Negative Staphylococcusepidermidis ATCC E155 0 Negative Stenotrophomonas maltophila ATCC 136370 Negative Streptococcus mitis ATCC 6249 0 Negative Streptococcus mutansATCC 25175 0 Negative Streptococcus pneumoniae ATCC 6303 0 NegativeStreptococcus pyogenes ATCC 19615 0 Negative Veillonella parvula ATCC10790 0 Negative Vibrio parahaemolyticus ATCC 17802 0 Negative Yersiniaenterolitica ATCC 27729 0 Negative SARS-CoV Positive Control Not 51 Positive Applicable SARS-CoV Positive Control Not 50  PositiveApplicable SARS-CoV Positive Control Not 51  Positive ApplicableSARS-CoV Positive Control Not 50  Positive Applicable SARS-CoV NegativeControl Not 0 Negative Applicable SARS-CoV Negative Control Not 0Negative Applicable SARS-CoV Negative Control Not 0 Negative ApplicableSARS-CoV Negative Control Not 0 Negative Applicable *Negative uponrepeat testing; initial result positive (PAT score = 48) due tolaboratory contamination BD: BD Diagnostics ATCC: American Type CultureCollection PAT scores >0 were considered positive

1. A oligonucleotide set comprising a first amplification primer and asecond amplification primer, the first amplification primer consistingessentially of SEQ ID NO.: 2 or 14 and the second amplification primerconsisting essentially of SEQ ID NO.: 3 or
 15. 2. The oligonucleotideset of claim 1 wherein the first amplification primer consistsessentially of SEQ ID NO.: 2 and the second amplification primerconsists essentially of SEQ ID NO.: 3 or the first amplification primerconsists essentially of SEQ ID NO.: 14 and the second amplificationprimer consists essentially of SEQ ID NO.:
 15. 3. (canceled)
 4. Aoligonucleotide set comprising a first amplification primer and a secondamplification primer, the first amplification primer consistingessentially of the target binding sequence of SEQ ID NO.: 2 or 14 andthe second amplification primer consisting essentially of the targetbinding sequence of SEQ ID NO.: 3 or
 15. 5. The oligonucleotide set ofclaim 4 wherein the first amplification primer consists essentially ofthe target binding sequence of SEQ ID NO.: 2 and the secondamplification primer consists essentially of the target binding sequenceof SEQ ID NO.: 3 or the first amplification primer consists essentiallyof the target binding sequence of SEQ ID NO.: 14 and the secondamplification primer consists essentially of the target binding sequenceof SEQ ID NO.:
 15. 6. (canceled)
 7. The oligonucleotide set of claim 1,further comprising a signal primer and a reporter probe, the signalprimer consisting essentially of the target binding sequence of SEQ IDNO.: 4, 5, 16 or 17 and the reporter probe consisting essentially of SEQID NO.: 8 or
 10. 8. The oligonucleotide set of claim 7, wherein thesignal primer consists essentially of the target binding sequence of SEQID NO.: 4 and the reporter probe consists essentially of SEQ ID NO.: 8,the signal primer consists essentially of the target binding sequence ofSEQ ID NO.: 5 and the reporter probe consists essentially of SEQ ID NO.:10, the signal primer consists essentially of the target bindingsequence of SEQ ID NO.: 16 and the reporter probe consists essentiallyof SEQ ID NO.: 8, the signal primer consists essentially of the targetbinding sequence of SEQ ID NO.: 17 and the reporter probe consistsessentially of SEQ ID NO.:
 10. 9. (canceled)
 10. (canceled) 11.(canceled)
 12. The oligonucleotide set of claim 7, further comprisingone or more bumper primers consisting essentially of SEQ ID NO.: 1, 12or
 13. 13. The oligonucleotide set of claim 8, wherein the signal primerconsists essentially of the target binding sequence of SEQ ID NO.: 5 andthe reporter probe consists essentially of SEQ ID NO.: 10 and furthercomprising a second reporter probe consisting essentially of SEQ ID NO.:11.
 14. The oligonucleotide set of claim 13, further comprising one ormore bumper primers consisting essentially of SEQ ID NO.: 1, 12 or 13.15. The oligonucleotide set of claim 8, wherein the signal primerconsists essentially of the target binding sequence of SEQ ID NO.: 17and the reporter probe consists essentially of SEQ ID NO.: 10 andfurther comprising a second signal primer and a second reporter probe,the second signal primer consisting essentially of SEQ ID NO.: 17 andthe second reporter probe consisting essentially of the hybridizationsequence of SEQ ID NO.:
 10. 16. The oligonucleotide set of claim 15,further comprising one or more bumper primers consisting essentially ofSEQ ID NO.: 1, 12 or
 13. 17. The oligonucleotide set of claim 4, whereinthe target binding sequences of SEQ ID NOs.: 2, 3, 14 and 15 comprise asequence required for an amplification reaction.
 18. The oligonucleotideset of claim 17, wherein the sequence required for the amplificationreaction comprises a restriction endonuclease recognition site that isnickable by a restriction endonuclease or a promoter recognized by anRNA polymerase.
 19. (canceled)
 20. The oligonucleotide set of claim 7,wherein the hybridization sequences of SEQ ID NOs.: 4, 5, 8, 9, 10, 11,16 and 17 further comprise an indirectly detectable marker. 21.(canceled)
 22. The oligonucleotide set of claim 4, further comprising asignal primer and a reporter probe, the signal primer consistingessentially of the target binding sequence of SEQ ID NO.: 4, 5, 16 or 17and the reporter probe consisting essentially of SEQ ID NO.: 8, 9, 10 or11.
 23. The oligonucleotide set of claim 22, wherein the signal primerconsists essentially of the target binding sequence of SEQ ID NO.: 4 andthe reporter probe consists essentially of SEQ ID NO.: 8, the signalprimer consists essentially of the target binding sequence of SEQ IDNO.: 5 and the reporter probe consists essentially of SEQ ID NO.: 10,the signal primer consists essentially of the target binding sequence ofSEQ ID NO.: 16 and the reporter probe consists essentially of SEQ IDNO.: 8, or the signal primer consists essentially of the target bindingsequence of SEQ ID NO.: 17 and the reporter probe consists essentiallyof SEQ ID NO.:
 10. 24. (canceled)
 25. (canceled)
 26. (canceled)
 27. Theoligonucleotide set of claim 22, further comprising one or more bumperprimers consisting essentially of SEQ ID NO.: 1, 12 or
 13. 28. Theoligonucleotide set of claim 23, wherein the signal primer consistsessentially of the target binding sequence of SEQ ID NO.: 5 and thereporter probe consists essentially of SEQ ID NO.: 10, and furthercomprising a second reporter probe consisting essentially of SEQ ID NO.:11.
 29. The oligonucleotide set of claim 28, further comprising one ormore bumper primers consisting essentially of SEQ ID NO.: 1, 12 or 13.30. The oligonucleotide set of claim 23, wherein the signal primerconsists essentially of the target binding sequence of SEQ ID NO.: 17and the reporter probe consists essentially of SEQ ID NO.: 10 andfurther comprising a second signal primer and a second reporter probe,the second signal primer consisting essentially of SEQ ID NO.: 17 andthe second reporter probe consisting essentially of the hybridizationsequence of SEQ ID NO.:
 10. 31. The oligonucleotide set of claim 30,further comprising one or more bumper primers consisting essentially ofSEQ ID NO.: 1, 12, 13 or
 20. 32. The oligonucleotide set of claim 4,wherein the target binding sequences of SEQ ID NOs.: 2, 3, 14 and 15comprise a sequence required for an amplification reaction.
 33. Theoligonucleotide set of claim 32, wherein the sequence required for theamplification reaction comprises a restriction endonuclease recognitionsite that is nickable by a restriction endonuclease or a promoterrecognized by an RNA polymerase.
 34. (canceled)
 35. The oligonucleotideset of claim 32, wherein the hybridization sequences of SEQ ID NOs.: 4,5, 8, 9, 10, 11, 16 and 17 further comprise an indirectly detectablemarker.
 36. (canceled)
 37. An oligonucleotide comprising a SARSCoronavirus (SARS-CoV) target sequence consisting essentially of SEQ IDNO.: 6, 7, 18 or
 19. 38. A method for detecting the presence or absenceSARS-CoV in a sample, the method comprising: (a) treating the samplewith a plurality of nucleic acid primers in a nucleic acid amplificationreaction wherein a first primer consists essentially of the targetbinding sequence of SEQ ID NO.: 2 or 14 and a second primer consistsessentially of the target binding sequence of SEQ ID NO.: 3 or 15; and(b) detecting any amplified nucleic acid product, wherein detection ofthe amplified product indicates presence of SARS CoV. 39-45. (canceled)46. A method for amplifying a target nucleic acid sequence of SARS-CoVcomprising: (a) hybridizing to the nucleic acid (i) a firstamplification primer consisting essentially of the target bindingsequence of SEQ ID NO.: 2 or 14; and (ii) a second amplification primerconsisting essentially of the target binding sequence of SEQ ID NO.: 3or 15; and (b) extending the hybridized first and second amplificationprimers on the target nucleic acid sequence whereby the target nucleicacid sequence is amplified. 47-57. (canceled)
 58. A method ofquantifying the amount of SARS-CoV nucleic acid in a target samplecomprising the steps of: a) combining the target sample with a knownconcentration of SARS-CoV internal control nucleic acid; b) amplifyingthe target nucleic acid and internal control nucleic acid in anamplification reaction; c) detecting the amplified nucleic acid; and d)analyzing the relative amounts of amplified SARS-CoV target nucleic acidand internal control nucleic acid.
 59. The method of claim 58, whereinthe amplification reaction utilizes one or more signal primersconsisting essentially of the hybridization sequence of SEQ ID NO.: 4,5, 16 or 17 and one or more reporter probes consisting essentially ofthe hybridization sequence of SEQ ID NO.: 8, 9, 10 or
 11. 60. The methodof claim 59, wherein the hybridization sequences of SEQ ID NOs.: 4, 5,8, 9, 10, 11, 16 and 17 comprise an indirectly detectable marker. 61-63.(canceled)